Immix Biopharma to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Immix Biopharma (NASDAQ:IMMX) will present and host investor meetings at two institutional conferences in Miami Beach in March 2026. Management will attend the Leerink Partners 2026 Global Healthcare Conference March 8–11 and Citizens Life Sciences Conference March 10–11, 2026.

One-on-one meetings are available via conference representatives; replay links will be posted on the company Presentation & Events page when available.

LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host investor meetings at the following upcoming institutional investor conferences:

• Leerink Partners 2026 Global Healthcare Conference being held March 8-11, 2026 in Miami Beach, FL.

• The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami Beach, FL.

Company management will host one-on-one meetings during the conferences. Interested investors should contact their Leerink or Citizens representative to request meetings. A link to access replays, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Company Contact
irteam@immixbio.com

FAQ

When will Immix Biopharma (IMMX) present at the Leerink Partners 2026 Global Healthcare Conference?

Immix Biopharma will present at the Leerink conference during March 8–11, 2026. According to the company, management will also host one-on-one investor meetings at the event in Miami Beach, Florida.

Will Immix Biopharma (IMMX) attend the Citizens Life Sciences Conference in March 2026?

Yes. Immix Biopharma will attend the Citizens Life Sciences Conference March 10–11, 2026. According to the company, management plans to host one-on-one investor meetings during the Miami Beach conference dates.

How can investors request one-on-one meetings with Immix Biopharma (IMMX) at the March 2026 conferences?

Investors should contact their Leerink or Citizens conference representative to request meetings. According to the company, meeting scheduling is handled through the respective conference organizers and their investor-relations teams.

Will Immix Biopharma (IMMX) post replays of its March 2026 conference presentations?

Yes, replay links will be posted to the investor section. According to the company, replays will be available on the Presentation & Events page of the Immix website when posted.

What topics will Immix Biopharma (IMMX) cover in its March 2026 investor presentations?

The company will present recent developments and host investor meetings at the conferences. According to the company, presentations will cover corporate updates relevant to investors and stakeholders attending the events.

Where are the March 2026 Leerink and Citizens conferences attended by Immix Biopharma (IMMX) being held?

Both conferences are taking place in Miami Beach, Florida in March 2026. According to the company, Leerink runs March 8–11 and Citizens runs March 10–11, with Immix management onsite.